(Reuters) – Gilead Sciences Inc said on Monday that it plans to begin clinical trials of an inhaled version of its antiviral treatment remdesivir for COVID-19 patients in August.
The drug is currently used intravenously and an inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside hospitals, the company said in a statement. (https://bit.ly/3eqpEJ9)
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
